Lanario Joseph W, Burns Lorna
Faculty of Health, University of Plymouth, Plymouth, UK.
J Asthma Allergy. 2021 Aug 12;14:999-1010. doi: 10.2147/JAA.S320817. eCollection 2021.
Asthma Health Related Quality of Life (HRQoL) is an outcome important to patients with severe asthma and can provide clinicians with additional insight into the benefits of treatment. The aim of this systematic review is to examine the use and reporting of HRQoL questionnaires within randomised controlled trials (RCTs) of biologics, fevipiprant and bronchial thermoplasty.
We followed the guidelines on the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statement. Of the 2380 retrieved articles, 52 studies were identified for inclusion.
Sixty-three percent included an asthma HRQoL questionnaire. It was a secondary outcome in the majority of cases (73%). The proportion of studies including an asthma HRQoL questionnaire did not change significantly over a 20-year period. While the Asthma Quality of Life Questionnaire (AQLQ) was used in 45% of studies, 55% used a variety of 4 questionnaires. Most (70%) of the studies that included a HRQoL questionnaire did not report its subscale scores. Approximately half (52%) of studies that used HRQoL reported this in the abstract of the paper. A higher proportion of studies used an asthma control questionnaire compared to a HRQoL questionnaire (71% vs 63%).
In order to increase the use of asthma HRQoL questionnaires in RCTs of severe asthma treatments, the drivers and barriers to their use must first be understood. At present, the patients' perspective is underrepresented in RCTs of biologics, fevipiprant and bronchial thermoplasty for severe asthma.
哮喘健康相关生活质量(HRQoL)是对重度哮喘患者很重要的一项结果,可为临床医生提供有关治疗益处的更多见解。本系统评价的目的是研究在生物制剂、法维吡兰特和支气管热成形术的随机对照试验(RCT)中HRQoL问卷的使用和报告情况。
我们遵循系统评价和Meta分析的首选报告项目(PRISMA)声明的指南。在检索到的2380篇文章中,确定了52项研究纳入。
63%的研究纳入了哮喘HRQoL问卷。在大多数情况下(73%),它是次要结果。在20年期间,纳入哮喘HRQoL问卷的研究比例没有显著变化。虽然45%的研究使用了哮喘生活质量问卷(AQLQ),但55%的研究使用了4种问卷中的多种。大多数(70%)纳入HRQoL问卷的研究未报告其分量表得分。使用HRQoL的研究中约有一半(52%)在论文摘要中报告了这一点。与HRQoL问卷相比,使用哮喘控制问卷的研究比例更高(71%对63%)。
为了增加哮喘HRQoL问卷在重度哮喘治疗RCT中的使用,必须首先了解其使用的驱动因素和障碍。目前,在生物制剂、法维吡兰特和支气管热成形术治疗重度哮喘的RCT中,患者的观点代表性不足。